

Understanding HER2-Positive Breast Cancer (BC)

Resource	Address
Baselga J, Coleman RE, Cortés J, Janni W. Advances in the management of HER2-positive early breast cancer. <i>Crit Rev Oncol Hematol</i> . 2017;119:113-122.	https://www.sciencedirect.com/science/article/abs/pii/S1040842817303517
Burstein HJ. The distinctive nature of HER2-positive breast cancers. <i>N Engl J Med</i> . 2005;353:1652-1654.	https://www.nejm.org/doi/full/10.1056/NEJMp058197
Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. <i>Oncologist</i> . 2009;14:320-368.	https://academic.oup.com/oncolo/article/14/4/320/6397834
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/ <i>neu</i> oncogene. <i>Science</i> . 1987;235:177-182.	https://www.science.org/doi/10.1126/science.3798106
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. <i>N Engl J Med</i> . 2001;344:783-792.	https://www.nejm.org/doi/full/10.1056/NEJM200103153441101

Targeted Therapy in HER2-positive Metastatic BC (mBC)

Resource	Address
Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. <i>N Engl J Med</i> . 2012;366:109-119.	https://www.nejm.org/doi/full/10.1056/NEJMoa1113216
Bourdeanu L, Luu T. Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer. <i>Clin J Oncol Nurs</i> . 2013;17:E58-E62.	https://www.ons.org/cjon/17/5/nursing-perspectives-trastuzumab-emtansine-treatment-metastatic-breast-cancer
Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis. <i>Ann Oncol</i> . 2022;33:321-329.	https://www.annalsofoncology.org/article/S0923-7534(21)04879-1/fulltext
Dent SF, Morse A, Burnette S, Guha A, Moore H. Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer. <i>Curr Oncol Rep</i> . 2021;23:128.	https://link.springer.com/article/10.1007/s11912-021-01114-x
Geyer C, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. <i>N Engl J Med</i> . 2006;355:2733-2743.	https://www.nejm.org/doi/full/10.1056/NEJMoa064320
Grinda T, Antoine A, Jacot W, et al. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort. <i>ESMO Open</i> . 2021;6:100114.	https://www.esmoopen.com/article/S2059-7029(21)00072-7/fulltext

Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial. <i>Lancet Oncol.</i> 2017;18:743-754.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30313-3/fulltext
Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. <i>Cancer Res.</i> 2008;68:9280-9290.	https://aacrjournals.org/cancerres/article/68/22/9280/542757/Targeting-HER2-Positive-Breast-Cancer-with
LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. <i>Clin Cancer Res.</i> 2011;17:6437-6447.	https://aacrjournals.org/clincancerres/article/17/20/6437/76533/Trastuzumab-Emtansine-A-Unique-Antibody-Drug
Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. <i>N Engl J Med.</i> 2020;382:610-621.	https://www.nejm.org/doi/10.1056/NEJMoa1914510
Murthy R, Borges VF, Conlin A, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: A non-randomised, open-label, phase 1b study. <i>Lancet Oncol.</i> 2018;19:880-888.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30256-0/fulltext
Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. <i>N Engl J Med.</i> 2019;382:597-609.	https://www.nejm.org/doi/10.1056/NEJMoa1914609
Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. <i>Chem Pharm Bull (Tokyo).</i> 2019;67:173-185.	https://www.jstage.jst.go.jp/article/cpb/67/3/67_c18-00744/article
Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. <i>Clin Cancer Res.</i> 2016;22:5097-5108.	https://aacrjournals.org/clincancerres/article/22/20/5097/124857/DS-8201a-A-Novel-HER2-Targeting-ADC-with-a-Novel
Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. <i>Cancer Sci.</i> 2016;107:1039-1046.	https://onlinelibrary.wiley.com/doi/10.1111/cas.12966
Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. <i>Nat Rev Clin Oncol.</i> 2020;17:33-48.	https://www.nature.com/articles/s41571-019-0268-3
Pondé N, Aftimos P, Piccart M. Antibody-drug conjugates in breast cancer: A comprehensive review. <i>Curr Treat Options Oncol.</i> 2019;20:37.	https://link.springer.com/article/10.1007/s11864-019-0633-6

Saura C, Oliviera M, Feng YH, et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. <i>J Clin Oncol</i> . 2019;37(15_suppl):1002.	https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.1002
Saura C, Oliviera M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial. <i>J Clin Oncol</i> . 2020;38:3138-3149.	https://ascopubs.org/doi/10.1200/JCO.20.00147
Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. <i>Lancet Oncol</i> . 2020;21:519-530.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30863-0/fulltext
Trail PA, Dubowchik GM, Lowinger TB. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. <i>Pharmacol Ther</i> . 2018;181:126-142.	https://www.sciencedirect.com/science/article/abs/pii/S0163725817301936
Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. <i>N Engl J Med</i> . 2012;367:1783-1791.	https://www.nejm.org/doi/10.1056/NEJMoa1209124
von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. <i>J Clin Oncol</i> . 2009;27:1999-2006.	https://ascopubs.org/doi/10.1200/JCO.2008.19.6618
Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): A multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncol</i> . 2021;22:351-360.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30702-6/fulltext

Adverse Events with Targeted Therapy

Resource	Address
Abuhelwa Z, Alloghbi A, Alqahtani A, Nagasaka M. Trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies: A systematic review. <i>Drugs</i> . 2022;82:979-987.	https://link.springer.com/article/10.1007/s40265-022-01736-w
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>J Clin Oncol</i> . 2018;36:1714-1768.	https://ascopubs.org/doi/10.1200/JCO.2017.77.6385

Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis. <i>Ann Oncol.</i> 2022;33:321-329.	https://www.annalsofoncology.org/article/S0923-7534(21)04879-1/fulltext
Hackshaw, MD, Danysh HE, Singh J, et al. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. <i>Breast Cancer Res Treat.</i> 2020;183:23-39.	https://link.springer.com/article/10.1007/s10549-020-05754-8
Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. <i>N Engl J Med.</i> 2020;382:610-621.	https://www.nejm.org/doi/10.1056/NEJMoa1914510
Mudd TW, Guddati AK. Management of hepatotoxicity of chemotherapy and targeted agents. <i>Am J Cancer Res.</i> 2021;11:3461-3474.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332851/
Pessi MA, Zilembo N, Haspinger ER, et al. Targeted therapy-induced diarrhea: A review of the literature. <i>Crit Rev Oncol Hematol.</i> 2014;90:165-179.	https://www.sciencedirect.com/science/article/abs/pii/S1040842813002552
Saura C, Oliviera M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial. <i>J Clin Oncol.</i> 2020;38:3138-3149.	https://ascopubs.org/doi/10.1200/JCO.20.00147
Skeoch S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: A systematic review. <i>J Clin Med.</i> 2018;7:356.	https://www.mdpi.com/2077-0383/7/10/356
Tarantino P, Modi S, Tolaney SM, et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: A review. <i>JAMA Oncol.</i> 2021;7:1873-1881.	https://jamanetwork.com/journals/jamaoncology/article-abstract/2784880
Wolska-Washer A, Robak, T. Safety and tolerability of antibody-drug conjugates in cancer. <i>Drug Safety.</i> 2019;42:295-314.	https://link.springer.com/article/10.1007/s40264-018-0775-7
Xuhong JC, Qi XW, Zhang Y, Jiang J. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. <i>Am J Cancer Res.</i> 2019;9:2103-2119.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834479/

Complimentary
poster for the
office!

Supplement your
Course Learning.
It's fast and easy.



We'll ship it
to you directly
free of charge

Translating Clinical Trial Findings into Practice:
Optimizing Treatment of Individuals with

METASTATIC HER2-POSITIVE BREAST CANCER

*For more information and
additional resources please visit*

[HTTPS://HER2MBC.POSTERPORTAL.COM](https://HER2MBC.POSTERPORTAL.COM)

